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Diabetic cardiomyopathy (DC) is an established cause of morbidity and mortality in individuals 
with diabetes mellitus (DM).  However, its molecular causes remain poorly defined.  Supra-
physiologic level of the α-oxoaldehyde methylglyoxal (MG) has emerged as a possible candidate 
since it can promotes many of the pathobiologies reported in DC.  If and how MG production/flux 
is increased in the heart during DM remains unclear.  Here ventricular tissues from patients and 
rats were used to assess protein levels of the MG synthesizing and degradation enzymes, vascular 
adhesion protein-1 (VAP-1) and glyoxalase-I (Glo-I), respectively.  A rat model of DM was also 
used to determine if preventing Glo-I downregulation would be cardio-protective, establishing 
cause and effect.  In ventricular tissues from patients and rats with DM, VAP-1 was upregulated 
in coronary microvascular smooth muscle cells (cSMCs) and Glo-I was reduced in cSMCs and 
myocytes.  MG was also increased.  Preventing Glo-I downregulation in cSMCs and myocytes of 
DM rats using a custom-engineered adeno-associated virus, lowered MG production/flux and 
blunted myocyte dysregulation and HF/DC.  Preventing Glo-I downregulation blunted VAP-1 
upregulation, prevented microvascular leakage, reduced oxidative stress and inflammation in 
ventricular myocytes, and minimized formation of MG adduct on and dysregulation of the 
sarcoplasmic reticulum Ca2+ cycling proteins, RyR2 and SERCA2a.   These new data suggest that 
MG production/flux is enhanced in DM hearts via upregulation of VAP-1 in cSMCs.  They also 
suggest that preventing Glo-I downregulation in cSMCs and myocytes could be a viable strategy 
to blunt diabetic DC development. 
 
Number of words = 246 
Nearly half a billion individuals worldwide have diabetes mellitus (DM), the syndrome that 
arises when insulin-producing β-cells of the pancreas are destroyed (Type 1 DM), the response of 
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peripheral organs/tissues to insulin is blunted (Type 2 DM), or both (usually late stage Type 2 
DM) (1, 2). The good news is that diverse array of glucose-lowering agents, food management, 
exercise and education initiatives are available to help individuals with DM regulate their blood 
glucose levels to near physiologic levels (3-5).  The not so good news is that a significant number 
of patients with DM are unable to regulate their blood glucose to the desired levels on a daily 
basis (4). One of the long-term consequences of inadequate glucose regulation is a 3-5 fold 
increase in the incidence of cardiovascular diseases (1).  More recent data also suggest that in 
some patients with chronic Type 2 DM, tight glycemic control may promote cardiovascular 
morbidity and mortality (6-7), prompting a search for glucose-independent mechanisms that 
contribute to cardiovascular diseases in DM. 
The heart is one of the organs whose function is negatively impacted by chronic/long-term 
DM.  Longitudinal, cross-sectional and meta-analysis studies over the past forty years have 
confirmed this heart failure or diabetic cardiomyopathy (DC) as it is commonly referred to, starts 
as a delay in left ventricular relaxation (diastolic dysfunction) and gradually worsens to 
impairment of left ventricular contraction (systolic dysfunction) (8-11).  Perturbation in myocyte 
intracellular Ca2+ handling, mitochondrial dysfunction, remodeling of the extracellular 
matrix/fibrosis, oxidative stress and inflammation, and endothelial dysfunction/microvascular 
disease, all contribute to the decline in left ventricular (myocyte) function (8-11).  However, it 
is not clear whether these diverse pathobiologies seen in both Type 1 and Type 2 DM are 
originating from a single or multiple independent cues.   
Methylglyoxal (MG) is an α-oxoaldehyde produced inside cells from the spontaneous and 
enzyme-catalyzed breakdown of the glycolytic pathway intermediates glyceraldehyde 3-
phosphate (G3P) and dihydroxyacetone phosphate (DHAP) (12-13). Thornalley estimated about 
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0.1% of glucotriose flux in red blood cells (RBCs) is converted to MG, equivalent to ~ 5.2 nmol 
MG/g RBCs/hour under normal glycemic conditions (14). Low MG regulates a diverse array of 
cellular and physiological functions including, cell differentiation, proliferation, anxiety, 
behavior, and sleep (15-22). Glyoxal is another structurally-related α-oxoaldehyde that it is 
generated from lipid peroxidation, the slow, spontaneous oxidative degradation of glucose and 
from degradation of glycated proteins. To date, its physiological role is not clearly defined (23), 
but it can be used as a marker of oxidative stress.    
Several laboratories including ours have shown that supra-physiological amounts of α-
oxoaldehydes, especially MG can elicit many of the pathobiologies reported in DC including 
impairment in endothelial cell function, perturbation in myocyte intracellular Ca2+ homeostasis, 
increases in ROS and inflammation and remodeling the extracellular matrix (24-29), making 
elevated MG a possible candidate for the varied pathobiologies seen in DC.  However, is not 
clear if and how MG production/flux would increase in the heart during DM, especially since its 
primary source, glycolytic flux, is attenuated; the diabetic heart obtain >90% of the acetyl CoA 
needed for ATP production from β-oxidation of fatty acids (30).  This dilemma led us to 
hypothesize that in the diabetic heart MG production/flux could increase if its production from 
non-glycolytic sources is increased or if its degradation is reduced. 
Vascular adhesion protein-1 (VAP-1, AOC3, EC 1.4.3.21) is best known as the adhesin that is 
upregulated on high endothelial venules at inflammatory sites to aid in the extravasation of 
leukocytes from the blood into tissues (31).  A less sialylated, but more glycosylated variant of 
VAP-1, is also expressed in low levels on the membrane of smooth muscle cells (SMCs) and 
adipocytes where it functions solely as the Cu2+ amine oxidase to deaminate the 
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glycine/threonine/tyrosine metabolite, aminoacetone to produce MG (32).  VAP-1 is also 
upregulated by inflammation on smooth muscle cells.   
MG (and glyoxal) is degraded in the cytoplasm of cells by the dual enzyme glyoxalase system 
(13, 33).  Glyoxalase-I, (GLOI, EC4.4.1.5) is the rate-limiting enzyme and catalyzes the 
formation of S-2-hydroxyacylglutathione derivatives formed from the reaction of the α-
oxoaldehydes and reduced glutathione (GSH).  The second enzyme glyoxalase-II (GLOII, EC 
3.1.2.6) which is also in the cytoplasm, catalyzes the hydrolysis of S-2-hydroxyacylglutathione 
derivatives to aldonates, liberating GSH.  Three other cellular enzymes can also degrade MG (and 
other α-oxoaldehydes); aldehyde dehydrogenase, 2-oxoaldehyde dehydrogenase, and aldose 
reductase, albeit with significantly higher Km values than Glo-I (34).    
In this study we tested our hypothesis by first assessing steady state levels of VAP-1, Glo-I 
and MG levels in ventricular tissues from patients (Type 1 and Type 2), and in a rodent model of 
DM (streptozotocin-induced rats).  We also used a gene transfer approach (an adeno-associated 
virus driven by the endothelin-1 promoter) to determine if preventing Glo-I downregulation in 
cSMCs and ventricular myocytes of DM rats would be sufficient to attenuate DC development 
later in the disease, establishing cause and effect. 
 
 
Number of words = 797 
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METHODS 
Antibodies and reagents 
Primary antibodies use for the study were obtained from AbCam Inc, Cambridge MA (von 
Willerbrand factor, vWF, sheep polyclonal, Cat# ab11713, smooth muscle actin alpha, SM22α, 
rabbit polyclonal, Cat# ab14106, goat polyclonal, Cat# ab10135); Novus Biological LLC, 
Littleton, CO (mouse monoclonal SM22α, Cat# NBP2-00894); JaiCA, Shizuoka, Japan 
(argpyrimidine Arg, Cat# JAI-MMG-030N); Santa Cruz Biotechnology Inc., Santa Cruz, CA 
(Glo-I [FL-184], rabbit polyclonal, Cat# SC-67351; VAP-1 [E-19], goat polyclonal, Cat # sc-
13741; and actin [1-19], goat polyclonal Cat# SC-1616), CalBiochem/EMD Bioscience, Billerica, 
MA (VAP-1 [TK8-14], mouse monoclonal, Cat# OP190); Invitrogen Life Technologies, Grand 
Island NY (phospholamban, Cat# MA3-922, phospho phospholamban Ser 16/17, Cat#702369, 
RyR2, Cat # PA5-36121, SERCA2a, Cat # MA3-919) and Cell Signaling Technologies, Danves 
MA (NF-κB p65 Cat #8242 and phosphor-p65 (Ser536, NF-κB), Cat#3031).  Secondary 
antibodies were obtained from Invitrogen Life Technologies (goat anti-mouse IgG coupled to 
Alexa Fluor 594, Cat# A-11032, chicken-anti-rabbit IgG coupled to Alexa Fluor 488, Cat# A-
21441, donkey anti-goat IgG coupled to Alexa Fluor 488 Cat# A-11055, donkey anti-goat IgG 
coupled to Alexa 594 Cat# A11058, donkey-anti-sheep IgG coupled to Alexa Fluor 594, Cat# A-
11016); Santa Cruz Biotechnology, Inc. (Donkey anti rabbit IgG-HRP, Cat# sc-2305 Donkey anti 
goat IgG-HRP Cat# sc-2304) and Vector Laboratories, Burlingame, CA (Fluorescein rabbit anti-
rat IgG Cat# FI-4000, and peroxidase-conjugated anti-mouse IgG).   
Bovine serum albumin labeled with fluorescein isothiocyanate (BSA-FITC, Cat# A9771), 
2,3,5-triphenyltetrazolium chloride (Cat# T8877), sodium thiobutabarbital (Inactin® Cat# T133) 
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and glyoxalase-I (Cat# G4252-500) were from Sigma-Aldrich (St Louis, MO).  All other reagents 
used were of the highest grade commercially available. 
 
Collection and preparation of autopsied ventricular tissues from DM patients 
Rapid autopsied formalin-fixed, de-identified heart tissues from non-diabetic and diabetic patients 
(Type 1 and Type 2) were obtained from the Department of Pathology and Microbiology at the 
University of the Nebraska Medical Center (UNMC). Tissues were embedded into paraffin blocks 
by Tissue Core Facility at UNMC and 5 µm sections were cut and mounted on glass slides. 
 
Immuno-histochemistry on paraffin-embedded human ventricular tissues 
Immuno-histochemical staining was conducted on paraffin-embedded non-diabetic and DM 
sections for the SMC marker, smooth muscle actin (SM22α), VAP-1, Arg and Glo-I.  For this, 
slides containing ventricular sections were heated to 65°C for 2 hr.  Paraffin was then removed 
with xylene (3 changes, ten minutes each) and rehydrated in decreasing concentrations of ethanol 
(100%, 100%, 95%, 70%, 50%, and distilled water, three minutes each).  Antigens were retrieved 
by incubating slides in 0.01 M citric acid (pH 6.39) for 40 min at 95 °C.  Sections were then 
cooled to room temperature for 20 min and then blocked in 10% normal horse serum for 1 hour at 
RT and incubated overnight at 4 ºC with the respective primary antibodies (1:100 to 1:200).  The 
next day, sections were incubated with the corresponding secondary Alexa Fluor coupled 
antibodies (1:400 to 1:800).  Sections were then washed with PBS and mounted with Prolong 
Gold Mountant Anti-fade containing DAPI.  Images were then taken with a Nikon inverted 
fluorescence microscope (TE 2000) equipped with a CoolSNAP HQ2 CCD Camera 
(Photometrics, Tucson, AZ).  A Nuance EX multispectral imaging system (Cambridge Research 
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Instruments, Worburn, MA) fixed to a Nikon Eclipse E800 and image analysis software (Caliper 
Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) was used to quantitate changes of 
VAP-1, MG and Glo-I immunoreactivities (36) in a blinded manner using three consecutive 100 
X frames.   
 
Construction of adeno-associated viruses 
The University of Pennsylvania Vector Core Facility generated the adeno-associated viruses 
containing rat glyoxalase-I used in this study with support from the Gene Therapy Resource 
Program, GTRP # 1053.  More details on construction of rat Glo-I into the plasmid are provided 
in our recent publication (35). 
 
Induction, verification and treatment of DM rats  
Animal used for this study were approved by the Institutional Animal Care and Use Committee, 
University of Nebraska Medical Center and adhered to the Guide for the Care and Use of 
Laboratory Animals.  DM was induced in anesthetized male Sprague-Dawley rats using a single 
low-dose intravenous injection of streptozotocin (STZ, 40-45 mg/kg in 0.1 mL in citrate buffer 
pH 4.5).  Control animals were injected with the same volume of citrate buffer only as detailed 
earlier (29, 36).  
One week after injection of STZ (blood glucose >300 mg/dL), DM rats were randomly 
divided into four groups.  The first group received a single intravenous injection of AAV2/9-Glo-I 
driven by the endothelin-1 promoter (1.7×1012 viron particles/kg in sterile physiologic saline 
solution, DM-Endo-Glo-I), the second group received a single injection of AAV2/9-Endo-eGFP 
(a non-specific gene, 1.7×1012 viron particles/kg, DM-Endo-eGFP), the third remained untreated 
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for the duration of the 8 week study (DM) and a fourth group was injected with AAV2/9-Glo-I 
driven by the more global cytomegalovirus promoter (1.7×1012 viron particles/kg, DM-CMV-Glo-
I).  Rats injected with citrate buffer only (Con) were divided into two groups.  The first control 
group was injected with AAV2/9-Endo-eGFP (Con-Endo-eGFP), and the second group remained 
untreated (Con) for the duration of the study.  The endothelin-1 promoter was selected to drive 
expression of Glo-I in AAV2/9 since prior studies have shown that SMCs and myocytes express 
endothelin-1 (35).  The CMV promoter was used since it should increase expression of Glo-I 
expression in all cell types of the heart infected (37). The dose (multiplicity of infection) of virus 
used was selected from our recent study (35) and is in agreement with other studies (38-39).  
 
Well-being of animals 
Nest construction was used as a measure of the well-being of animals (35, 40).  Two hours prior 
to start of a dark-cycle, rats were transferred to clean, dry cage with a piece of cotton (11 ± 0.5 g, 
PetCo San Diego, CA) placed in one corner.  The next day, a five-point scale was used to score 
overnight nest construction; shredding and movement of <10% of cotton to center of cage = 1; 
shredding and movement of ~25% cotton to center of cage = 2; shredding and movement of ~50% 
to the center of cage = 3; shredding and movement of ~75% of cotton to the center of cage = 4; 
shredding and movement of 100% to the middle of cage = 5.   
 
Ventricular function in rats 
At the end of the 8 week study protocol, hair from the chests of rats was removed (Nair, Church 
& Dwight Co., Inc. NJ, USA).  The next day, rats were anesthetized with 5% isoflurane, taped in 
the supine position on a heated (37°C) pad and Pulse-wave echocardiography was performed to 
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assess peak flow velocity during early diastole (E) and peak flow velocity during atrial 
contraction (A) using a color flow–guided, pulsed-wave Doppler probe (716, 17.6-MHz). M-
mode echocardiography (short axis orientation) was also conducted to assess ventricular end 
diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), percent fractional 
shortening (% FS), percent ejection fraction (% EF), stroke volume and cardiac output using a 
built-in algorithm (29, 36). All echocardiographic studies were performed using a Vevo 770 High 
Resolution in Vivo Micro Imaging System (Fuji Film Visual Sonics Inc, Toronto Canada).   
 
Microvessel perfusion and permeability  
At the end of the 8-week protocol rats were injected intraperitoneally with heparin (100 unit/kg, 
i.p.).  Five min later, rats were anaesthetized (100 mg/kg sodium thiobutabital i.p.) and a single 
injection of bovine serum albumin coupled to fluoroscein isothiocynate (BSA-FITC, 40 mg/kg in 
sterile 1X PBS buffer, 50 µL) was injected via a vein under the tongue and allowed to circulate 
for 10 min (35).  After this, animals were euthanized, chest cavities were opened and hearts were 
quickly removed and immersed in 4% paraformaldehyde for 24 hr at 4°C.  The next day, hearts 
were transferred to 4% paraformaldehyde/15% sucrose solution for 24 hrs, followed by 4% 
paraformaldehyde/30% sucrose solution for 24 hrs, and then 30% sucrose solution for 24 hrs 
before storing at -80 ºC.  
Cryoprotected rat hearts were then cut into 20 μm thick longitudinally sections on a 
microtome (Leica EM-UC 6, Leica Microsystems, Wien, Austria) and mounted onto pre-cleaned 
glass slides.  Slices were then washed three times with 1X PBS to remove cutting medium.  
Vectashield mounting medium containing DAPI was added to the sections, slides were cover 
slipped and placed on the headstage of a Nikon TE2000 microscope attached to a Coolsnap HQ2 
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CCD camera (Photometrics, Tuscon AZ).  Images were then taken to assess the density of 
microvessels perfused with BSA-FITC, and for leakage of microvessels.   For determining the 
density of perfused microvessels, 100 X frames from three adjacent sections were analyzed.  To 
be counted as a perfused vessel, the vessel must contain BSA-FITC (green) in a length ≥ 40 µm.  
Branched vessels were counted as one vessel.  A vessel was counted as leaky if BSA-FITC was 
seen emanating from the confines of its microvessel walls. 
 
Isolation of rat ventricular myocytes 
Ventricular myocytes were isolated using the procedure described earlier (29, 36). For this, rats 
were injected intraperitoneally with heparin (1000 U/kg) 10 min prior to sacrifice with a lethal 
dose of Inactin® (75 mg/kg, i.p.). Chest cavities were opened, and hearts were removed with the 
aorta intact.  Excised hearts were placed in a Krebs–Henseleit (K–H) buffer (13.8 mM NaCl, 
4.0 mM KCl, 1.2 mM MgSO4, 0.9 mM NaH2PO4, 25 mM NaHCO3, 8.4 mM HEPES, 11.1 mM D-
glucose, 1 mM adenosine) and adventitious tissue around the aortas were removed.  Hearts were 
then mounted in the Langendorf configuration and perfused for 5–6 min at a flow rate of 6–
8 mL/min with K–H buffer containing 1.8 mM CaCl2 to remove blood from the vessels. The 
perfusion solution was then switched to Ca2+-free K–H and the hearts were perfused for an 
additional 10 min.  Hearts were then perfused in a recirculatory manner with Ca2+-free K–H 
buffer containing Type 2 collagenase (0.66–0.80 mg/mL) for 25–28 min. After digestion of the 
extracellular matrix, hearts were removed from the perfusion apparatus and the atria and aorta 
were trimmed away.  Ventricular tissues were then finely cut in buffer containing 0.25 mM 
Ca2+ and trituated to enhance myocyte release. Cells were filtered through nylon meshes (300 μm) 
and collected into 14 mL polypropylene cell culture tubes. Cells were then incubated for 10 min 
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at 37 ºC with gentle rotation.  Cells were then allowed to settle and half the supernatant was 
removed and replaced with K–H buffer containing 0.25 mM Ca2+. The process was repeated with 
0.5 mM, 0.75 mM and 1.0 mM Ca2+ to gradually restore Ca2+ tolerance.  Cells were resuspended 
in Dubelcco' modified eagle medium containing 1.8 mM Ca2+, supplemented with F-12 (1:1) and 
antibiotics (100 U/mL penicillin, 100 μg/mL streptomycin and 100 μg/mL gentamicin), pH 7.3, 
placed in a water-jacketed incubator at 37 °C and used within 5–6 hr after isolation. 
 
Contractile kinetics of rat myocytes 
A cohort of ventricular myocytes from each group of animals was used for assessment of 
mechanical properties using a high-speed video-based edge detection system (IonOptix 
Corporation, Milton, MA) (29, 36). For this, myocytes in DMEM were placed in a chamber 
mounted on the stage of an inverted microscope (Zeiss X-40, Thornwood, NJ) at room 
temperature (22 ºC – 24 ºC). Cells were then field stimulated (10 V, 10 ms at 0.5 Hz) using a pair 
of platinum wires placed on opposite sides of the chamber and contraction/relaxation were 
recorded using a proprietary data acquisition program (IonOptix Corporation, Milton, MA).  
Rates of myocyte shortening, relengthening, and extent of cell shortening were calculated using 
IonWizard, Version 5.0. 
 
Evoked SR Ca2+ release in rat ventricular myocytes 
A cohort of ventricular myocytes from each group was used to assess evoked Ca2+ release (29, 
36).  For this, freshly isolated ventricular myocytes attached to laminin-coated coverslips in 
DMEM-F12 medium were loaded with Fluo-3 (5 μM) for 30 min at 37 ºC.  After this, cells were 
washed to remove extracellular Fluo-3 and placed in a chamber on the stage of the confocal 
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microscope (Zeiss 510 confocal microscope, Carl Zeiss Inc., Thornwood, NY).  Cells were then 
field stimulated (0.5 Hz, 10 V, 10 ms) using a pair of platinum wires, and changes in fluorescence 
intensities (ΔF) were determined.  Fluo-3 was excited by light at 488 nm, and fluorescence was 
measured at wavelengths of >515 nm.  All experiments were performed in line-scan mode.  LSM 
Meta 5.0, Prism 5.0, and Microsoft Excel were used for analyzing rates of Ca2+ rise (linear 
regression) and decay constants (one-phase exponential decay).  
 
Immuno-histochemistry on paraformaldehyde-fixed rat ventricular tissues 
Immuno-histochemistry was also conducted on rat ventricular slices for VAP-1, argpyrimidine, 
Glo-I, and the smooth muscle actin alpha (SM22-α).   For this, 20 μm ventricular slices were 
permeabilized in 1X phosphate buffered saline containing using 0.1% Triton-X 100 and 10% 
normal horse serum for 1 hr at room temperature.  Slices were then washed three times with 1X 
PBS (5 min) and incubated with primary antibodies (1:100 to 1:200) for 16 hrs at 4 ºC.   At the 
end of the incubation, heart sections were washed three times with 1X PBS, and incubated in the 
dark for 1 hr with appropriate secondary antibodies coupled to Alexa Fluor 488 and 594 
antibodies (1:400 to 1:600) at room temperature.  Slices were then washed three times with 1 X 
PBS.  Vectashield mounting medium with DAPI was then added and slides were cover slipped.  
Images were then collected on a Nikon TE 2000 microscope and the Nikon Eclipse E800 and 
image analysis software (Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) 
was used for quantitate changes of VAP-1 and Glo-I.   
 
Steady-state levels of sarco(endo)plasmic reticulum Ca2+ cycling proteins, VAP-1 and Glo-I  
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Western blot assays were used to determine steady state levels of type 2 ryanodine receptor 
(RyR2), sarco(endo)plasmic reticulum Ca2+ATPase (SERCA2a), phospholamban (monomeric 
and pentameric), argpyrimidine (a MG adduct) VAP-1 and Glo-I using procedures described 
earlier (29, 35, 36).  For this, ventricular tissues (200 mg) were cut into small pieces and placed in 
600 µl of ice-cold buffer (0.3 M sucrose, 10 mM histidine and 230 μΜ of freshly dissolved 
phenylethylsufonyl fluoride, in 100% ethanol, pH 7.4) for 10 min.  Tissues were homogenized for 
3 X 5 sec (15 sec intervals homogenization, ProScientific, PRO 25, setting 4.5, Oxford, CT).  
Samples were then centrifuged for 10 min at 3000 rpm.  The supernatants were removed and 
protein concentrations were determined.  Protein samples (60-80 μg) were then dissolved in gel 
dissociation medium (62.5 mM Tris base, 6% SDS, 20% glycerol, and 0.002% bromphenol blue 
containing 12 mg dithiothreitol/mL) and heated to 50-55ºC for 15 minutes. After this, samples 
were electrophoresed using 4–15 or 4 to 20%  linear gradient polyacrylamide gels at 150 V for 
times varying from 1.0 to 3.5 hr, depending on protein of interest.  After electrophoresis, proteins 
were transferred onto polyvinyldiethylene difluoride membranes, blocked (0.01 M Tris-HCl, 0.05 
M NaCl, 5% bovine serum albumin, Sigma , and 0.04% Tween 20, pH 7.4) for 1 hr and incubated 
overnight with respective primary antibodies (1:1000), followed by the secondary antibodies 
(1:2000-2500) coupled to horse radish peroxidase.  Membranes, were exposed to a 1:1 dilution of 
ECL™ (or enhanced ECL™) Western Blot Detection Reagents (Invitrogen, NY) for 2 min and 
then exposed to blue ultra autoradiographic film 8x10, double emulsion blue (ISC BioExpress, 
Kaysville, UT).  β-actin served as the internal control to correct for variations in sample loading.  
Immunohistochemical assays were also performed to determine locations of VAP-1 and 
Glo-I in rat ventricular tissues rats.   For this, 20 μm ventricular slices were permeabilized in 1X 
phosphate buffered saline containing using 0.1% Triton-X 100 and 10% normal horse serum for 1 
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hr at room temperature.  Slices were then washed three times with 1X PBS (5 min) and incubated 
with primary antibodies (1:100 to 1:200) for 16 hrs at 4 °C.   At the end of the incubation, heart 
sections were washed three times with 1X PBS, and incubated in the dark for 1 hr with 
appropriate secondary antibodies coupled to Alexa Fluor 488 and 594 antibodies (1:400 to 1:600) 
at room temperature.  Slices were then washed three times with 1X PBS.  Vectashield mounting 
medium with DAPI was then added and slides were cover slipped.  Images were then collected on 
a Nikon TE 2000 microscope and the Nikon Eclipse E800 and image analysis software (Caliper 
Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA). Smooth muscle actin alpha 
(SM22-α) was used as a marker for smooth muscle cells of microvessels. 
 
Activities of sarco(endo)plasmic reticulum Ca2+cycling proteins, VAP-1 and Glo-I  
(a) SERCA2a activity: Ca2+ uptake assays (steps 1–6 of the post-Elbers cycle [E1→E2]) were also 
used to assess the activity of SERCA2a (36).  For this, sarcoplasmic reticular membrane vesicles 
were resuspended in 1 mL buffer (30 mmol/L Tris-HCl, pH 7.0; 100 mmol/L KCl; 5 mmol/L 
NaN3; 5 mmol/L MgCl2; 0.15 mmol/L EGTA; 0.12 mmol/L CaCl2; 1 μCi 45Ca2+; and 10 mmol/L 
potassium oxalate) and were divided into 2 × 500 μL aliquots. One aliquot was incubated with a 
thapsigargin (10 μmol/L), ammonium molybdate (100 μmol/L), bafilomycin (0.05 μg/mL) and 
ryanodine (50 μmol/L) for 15 min and the other remained untreated.  Ca2+ uptake was initiated by 
adding Na2ATP (3 mM) and aliquots (50 µL) were taken at 0, 10 and 20 min and filtered using 
Whatman GF/C filters (1.2 µm). The filters were then rinsed twice by using 3-mL portions of ice-
cold buffer (without 45Ca2+). A 50 µL aliquot was taken from each tube to verify the total 45Ca2+ 
content. Intravesicular 45Ca2+ was determined by liquid scintillation counting of the protein 
retained on the filters. 
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Ca2+-ATPase activity (steps 1–3 of the post-Elbers cycle) of SERCA2a was also assessed 
using the procedure earlier (36).   Briefly, membrane vesicles containing SERCA2a (equivalent 
amounts of proteins) were incubated in 500 μL buffer (10 mmol/L HEPES, pH 7.3; 0.1 mol/L 
KCl; 5 mmol/L Mg2+; 100 μmol/L Ca2+; 100 μmol/L EGTA; and 2.5 mmol/L Na2-ATP) and 
incubated for 20 min at 37°C in the presence and absence of the Ca2+ ionophore A23187 (2 
μg/mL).  After this time, reactions were stopped and the inorganic phosphate generated from ATP 
hydrolysis was assessed using the malachite green colorimetric assay described previously. 
(b) RyR2 activity: Ca2+-dependent binding of [3H]ryanodine (29) was used as an index of RyR2 
function.  In this assay, [Ca2+] ≤300 µM activate or open RyR2 thereby increasing [3H]ryanodine 
binding, while higher Ca2+ concentrations deactivate or close RyR2, decreasing [3H]ryanodine 
binding.  For this, sarcoplasmic reticular membrane vesicles (0.1 mg/mL) prepared as described 
earlier (29) were incubated in binding buffer (500 mM KCl, 20 mM Tris–HCl, 5 mM reduced 
glutathione, 100 μM EGTA, pH 7.4) for 2 hrs at 37 °C with 6.7 nM [3H]ryanodine and increasing 
amounts Ca2+ (13 nM to 5 mM). After incubation, proteins were filtered and washed, and the 
amount of [3H]ryanodine bound to RyR2 was determined using liquid scintillation counting. Non-
specific binding was determined simultaneously by incubating vesicles with 1000 nM unlabeled 
ryanodine. 
(c) Glyoxlase-I activities in rat ventricular homogenates were determined 
spectrophotometrically using procedure described earlier (35).  Briefly, in a 1 mL quartz cuvette, 
250 μL of 0.1 M NaPO4 buffer, pH 6.6, 233 μL of distilled water, 25 µL of 4 mM MG, and 50 μL 
of 2 mM reduced GSH were mixed and the absorbance at 240 nm was measured.  Thereafter, 500 
μg of homogenate from each group of animals were mixed and absorbance was recorded after 60 
and 120 sec at room temperature using a spectrometer (Smart Spec 3000, BioRad Inc, Burlingame 
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CA). A standard curve was generated using commercially available Glo-I standard (1.63 units per 
ug) and used for quantification. 
(d) VAP-1 activities in rat ventricular homogenates were assessed using SSAO assay kits (Cell 
Technology, Inc, Mountain View, CA) as per manufacturer instructions without modification.  
 
Determination of methylglyoxal and glyoxal levels in rat serum and ventricular tissues 
Methylglyoxal and glyoxal concentrations in serum and ventricular tissues were determined using 
a method optimized in our laboratory based on methods previously described by McLellan et al. 
(41-43).  Briefly, serum (500 µL) and rat ventricular tissues (~200 mg, finely chopped) were 
placed in 3X volume or 3X weight/volume of cold isolation buffer containing 0.3 M sucrose, 10 
mM histidine and 230 μΜ of freshly dissolved phenylethylsufonyl fluoride  in 100% ethanol, pH 
7.4.  Samples were placed on ice for 10-15 min.  After this, samples were homogenized for 3 X 5 
sec (15 sec interval wait in between homogenization, ProScientific, PRO 25, setting 4.5). The 
homogenized samples were mixed thoroughly with equal volumes of perchloric acid (5.0 M) and 
placed on ice for 10 min.  The samples were then centrifuged for 10 min at 3000 rpm (Eppendorf 
5417R, EL 129 FA 45-24-11 rotor).   Equal volumes of 0.1 M o-phenylenediamine prepared in 
1.6 M perchloric acid were then added to each sample, mixed, wrapped around in aluminum foil 
and allowed to react overnight at room temperature.  The reaction products were then extracted 
with 3 X 3 mL of chloroform and water was removed using anhydrous sodium sulfate (0.5 g).  
The chloroform from each extract was removed using a gentle stream of nitrogen.  The dried 
samples were then resuspended in 500 μL methanol and stored at -80°C until analyzed.   High 
performance liquid chromatography was performed of 5 µL injection of each sample in duplicate 
using (SCL-Shimadzu 10A, HPLC) employing a Kinetex 5μ C18 100R column using mobile 
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phase consisting of methanol: water: trifluoroacetic acid (52:48:0.1) at flow rate of 1 mL/min and 
wavelength of 312 nm.  Calibration curves were generated using 5 µL injections of varying 
concentrations (0.5 to 50 µM) of 2-methylquinoxaline (cat #W511609, Sigma-Aldrich, St Louis 
MO) and quinoxaline (cat # Q1603 Sigma-Aldrich).  In some samples (control and DM), o-
phenylenediamine was left of from the reaction mixture and in some of the prepared samples, 50 
µM mixture of 2-methylquinoxaline and quinoxaline were spiked in to identified peaks the 
retention times of the peaks of interest. 
 
Glutathione (GSH) and enzymes that regulate GSH production 
Glutathione (GSH) was measured in ventricular homogenates using a commercial kit according to 
manufacturer’s protocol (Oxis Research, Portland, OR).  Briefly, finely chopped ventricular 
tissues (~100 mg) from the various groups of animals were sonicated in 5% metaphosphoric acid 
and centrifuged at 4°C for 20 min (3000 X g) to precipitate proteins.  Supernatants were collected 
and total glutathione [GSH + oxidized glutathione (GSSG)] was determined by measuring the 
formation of 2-nitro-5-thiobenzoic acid at 412 nm (25°C) in the presence of 5,5′-dithio-bis-(2-
nitrobenzoic acid), NADPH, glutathione reductase, and EDTA. GSSG was also determined by 
derivatizing supernatants with 1-methyl-2-vinylpyridium trifluoromethane sulfonate and assaying 
the derivatized samples as above for total GSH. Standard curves for GSH and GSSG were 
constructed, and the [GSH] was calculated by subtracting the GSSG concentration from total 
glutathione (GSH+GSSG). Measured concentrations of GSH and GSSG were expressed in 
micromoles per liter per milligram protein and as a ratio (GSH/GSSG). 
Glutathione reductase and γ-glutamylcysteine ligase were also measured in ventricular tissues 
(35, 44).  Briefly, ventricular tissues (̇~200 mg) were homogenized in 600 µL of ice-cold Tris 
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buffer (0.1 mol/L, pH 8.0, with 2 mM EDTA) and centrifuged at 4°C (6,000 g) for 30 min as 
described earlier.  A 200 μL aliquot of the supernatant from each group of animals was added to a 
cuvette containing KH2PO4 buffer (0.2 M, pH 7.0) plus 2 mM EDTA, 20 mM GSSG, and 2 
mmol/L NADPH.   Changes in absorbance at 340 nm were monitored over 5 min at 25°C using a 
spectrophotometer.  A milliunit (mU) of glutathione reductase activity was defined as the amount 
of enzyme catalyzing the reduction of 1 nmol NADPH per minute. 
γ-Glutamylcysteine ligase activity was also determined (35, 45).  Ventricular homogenates 
were prepared as above and a 50-μl aliquot of the supernatant from each of animals was added to 
a reaction mixture containing 0.1 M Tris buffer and (in mM) 150 KCl, 5 Na2ATP, 2 
phosphoenolpyruvate, 10 L-glutamate, 10 L-α-aminobutyrate, 20 MgCl2, 2 Na2-EDTA, 0.2 
NADH, 17 μg pyruvate kinase and 17 μg lactate dehydrogenase. Changes in absorbance at 340 
nm were monitored for 5 min at 25°C, and γ-glutamylcysteine ligase activity was expressed in 
milliunits, defined as the activity converting 1 nmol of NADH to NAD per minute. 
 
Measurement of oxidative stress and inflammation  
Increases in oxidative stress and inflammation are characteristic features in the heart during DM 
(46-47).  Earlier we showed that acutely exposing ventricular myocytes from control rats to MG 
increased mitochondria production of reactive oxygen species (ROS) (29).  We also found 
increased production of the pro-inflammatory mediator, tumor necrosis factor alpha (TNF-α) at 
sites of vascular leakage (35).  These findings prompted us to investigate whether increasing Glo-
I in SMCs and myocytes of DM rats would lower ROS and inflammation.   
(a) Measurement of ROS: Freshly isolated ventricular myocytes were loaded with MitoTracker 
Green (100 nM, Life Technologies, Grand Island NY), followed by the fluorogenic, 
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mitochondria-targeted, reactive oxygen species (ROS) probe MitoSOX Red (2 μM), for 15 min 
each.  Cells were then washed 3X with fresh medium and placed on the stage of a Zeiss LSM 510 
Meta laser scanning microscope, The red fluorescence images of MitoSOX Red was captured 
by exciting at 488 nm with emission at 594 nm, while the green fluorescence of MitoTracker 
Green was collected by excited at 488 nm, with emission at 516 nm (29, 36).  MitoSOX Red 
fluorescence was quantified with ImageJ analysis software (http://rsbweb.nih.gov/ij/). 
(b) Measurement of NF-κB activity: Activation of the nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB) results in increased expression of pro-inflammatory genes including 
VAP-1 (48). In this study activation of this pathway was assessed by measuring the amount of 
phosphorylation of the p65 subunit of NF-κB using western blot assays.  For this, left ventricular 
tissues (100 mg) were cut into small pieces and placed in 300 µL of ice-cold lysis buffer (300 mM 
NaCl, 40 mM Tris-HCl, 2 mM EGTA, and 2 mM EDTA, 1% Triton X 100, 0.1% SDS, 
phosphatase inhibitor cocktails 1 and 2, pH 7.4) for 10 min.  Tissues were then sonicated for 3 X 
5 sec (15 sec intervals between sonications).  Lysates were then centrifuged for 10 min at 3000 
rpm.  Protein concentrations of the supernatants then determined. Lysates (75 μg) were then 
electrophoresed using 4–15% linear gradient polyacrylamide gels at 150 V for 1.5 hr.  After this, 
proteins were transferred onto polyvinyldiethylene difluoride membranes, blocked with 5% non-
fat milk for 1 hr and incubated overnight with phosphor-p65 (Ser536) and p65 antibodies 
(1:1000), followed by the secondary antibodies (1:2000-2500) coupled to horseradish peroxidase.  
Thereafter, membranes, were exposed to a 1:1 dilution of ECL™ Western Blot  Reagents 
(Invitrogen NY) for 2 min, exposed to autorad film (ISC BioExpress, Kaysville, UT) and the 
intensities of the signals were used as indices of the amount of protein.  Actin served as the 
internal control to correct for variations in sample loading.  
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(c) Measurement of TNF-α in rat ventricular tissues: Total RNA was extracted from freshly 
isolated, finely chopped rat ventricular tissues using Trizol and purified using RNeasy Mini Kit 
according to manufacturer’s protocol (Qiagen; Germantown, MD) described earlier (35).  RNA 
samples were treated with DNase I to remove any contamination DNA.  RNA concentrations and 
purity were measured at OD 260 and OD 280.  Total RNA with OD260/OD280 greater than 1.8 (1 
μg) were reverse-transcribed into cDNA using MLV reverse transcriptase (Invitrogen 
Corporation, Carlsbad, CA, USA) in 20 μL volume.  cDNA of each sample was used in Taqman 
real-time PCR to obtain the CT value for TNF-α in an ABI sequence detector (Applied 
Biosystems, Foster City, CA, USA).  The real-time PCR for β-actin was run in parallel and served 
as the PCR control. Each sample was run in triplicate in PCR to determine gene expression of 
TNF-α.  Primers used for TNF-α were 5’ ATG-AGC-ACT-GAA-AGC-ATG-AT and 3’ CTC-
TTG-ATG-GCA-GAG-AGG-AG (Integrated DNA Technologies (Coralville, IA).  Relative gene 
expression (RGE) was calculated from the CT values using the Delta CT method.  
 
Statistical Analysis 
Differences among each of the groups were evaluated using one-way analysis of variance 
(ANOVA) followed by the Bonferroni’s post-hoc test to determine if there was significant 
difference between Con and DM groups, and whether these changes were attenuated with 
treatment by using Prism GraphPad 6 (La Jolla, CA).  Data shown are means ± S.E.M.  Results 
were considered significantly different if p<0.05 (95% confidence interval).  
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RESULTS 
The general characteristics of non-diabetic and patients from which autopsied tissue samples were 
obtained are shown in Table 1.   There were no significant differences in mean age of non-
diabetic and DM patients and time to harvest tissue after death.  All patients had carried a 
diagnosis of DM for >25 years; however, specific information on glucose management or cardiac 
function during this period were not available. 
 
VAP-1, argpyrimidine and Glo-I immunoreactivity in human ventricular tissues 
In the majority of microvessels (100 to 250 µm) assayed from non-diabetic tissues, 66 out of 80, 
the endothelium was near continuous (intact) as determined from von Willerbrand factor 
immuno-reactivity (data not shown).  This can also be seen as an intense green auto-fluorescence 
on the inside of microvessels (Figure 1A, upper two panels).  In microvessels from Type 1 DM 
patients (>75 out of 90), the endothelial layer was disrupted (Figure 1A, third and fourth panels) 
and significantly less intense (p=0.03) than that in non-diabetic tissues.  In the majority of 
microvessels (62 out of 77 vessels) from Type 2 DM patients, their endothelial layers were also 
near continuous. There was a trend towards less intense green auto-fluorescence in the endothelial 
layer of microvessels from Type 2 DM compared to non-diabetic, but the difference did not attain 
significance (p=0.08).   
In coronary microvascular smooth muscle cells (cSMCs) from both T1DM and T2DM 
patients, VAP-1 immunoreactivity was 3- to 4-fold higher (Figures 1B, graph, p<0.05) and Glo-I 
immuno-reactivity was 2- to 2.5-fold lower than that in non-diabetic tissues (Figure 1A, upper 
graph, p<0.05).  Argpyrimidine (one of the two adducts formed on arginine residues by MG) was 
also significantly higher ventricular tissues from T1DM and T2DM patients (Figure 1C).    
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VAP-1, argpyrimidine and Glo-I immunoreactivity in left ventricular tissues from DM rats 
In ventricular tissues from 8 weeks DM rats VAP-1 was also increased in cSMCs while immuno-
reactive Glo-I was reduced in cSMCs and myocytes (Figures 2A and 2B).   Argpyrimidine 
immunoreactivity was also increased in ventricular tissues from DM rats (Figure 2C).   
Having established dysregulation of the VAP-1 - MG – Glo-I axis in human and rat 
ventricular tissues, we proceeded to use a custom-engineered adeno-associated to prevent Glo-I 
downregulation in cSMCs and myocytes and determine if lowering MG production/flux would be 
sufficient to attenuate myocyte dysregulation and DC in our rat model of DM.     
 
General characteristic of animals used in the study 
The general characteristics of animals used in this study are summarized in Table 2.   At the end 
of the 8 week experimental protocol, mean body weight of untreated DM rats was significantly 
lower than control rats.   Heart weight to body weight ratio was also significantly higher (p<0.05) 
in DM rats compared with controls, and this increase was partially attenuated with systemic 
injection of AAV2/9-Endo-Glo-I and AAV2/9-CMV-Glo-I, but not AAV2/9-Endo-eGFP.  There 
was a trend towards lower blood glucose levels in DM rats injected with AAV2/9-Endo-Glo-I, 
AAV2/9-CMV-Glo-I compared to DM but it did not attained statistical significance.   
  
Well-being of animals 
Nest building, which requires the complex interplay of attention, decision-making, motor 
function, and orofacial and forelimb movements, was used to assess overall well-being of animals 
at the end of the study.  Eight week DM rats were less inclined to shred the cotton and create a 
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nest in the center of the cage overnight (Figure 2D, white arrow and graph below).  The beddings 
of their cages were also “wetter” than controls, consistent with polydipsia/polyuria.  
Administering a single dose of AAV2/9-Endo-Glo-I one week after the onset of DM prevented 
impairment in overnight nest construction, assayed seven weeks later.  DM rats treated with 
AAV2/9-Endo-Glo-I also drank ~25% less water overnight than untreated DM rats and exhibited 
a significant reduction in overnight polyuria, (see Figure 2D white arrow).  Administering 
AAV2/9-CMV-Glo-I one week after the onset of DM, also preserved their ability to create a nest 
overnight in the  middle of the cage, but it was not as robust like AAV2/9-Endo-Glo-I treated DM 
rats  (Figure 2D).  Although AAV2/9-CMV-Glo-I treatment reduced polydipsia/polyuria, it was 
not as robust as with AAV2/9-Endo-Glo-I treated DM rats.  Injecting rats injected with a single 
dose of AAV2/9-Endo-eGFP one week after the onset of DM, did not preserve nest construction 
ability or reduced polydipsia/polyuria. Injecting control rats with AAV2/9-Endo-eGFP also not 
impair next building capabilities.  
 
Left Ventricular Function  
Peak flow velocity during early diastole (E), peak flow velocity during atrial contraction (A) and 
E-to-A ratios were decreased after 8 weeks of DM (representative examples shown in Figure 3A 
above, Table below shows mean data).  M-Mode echocardiographic analyses (short axis) also 
showed significant reductions in left ventricular fractional shortening after 8 weeks of DM 
(Figure 3B).  A single intravenous injection of AAV2/9-Endo-Glo-I one week after the onset of 
DM blunted the decrease in peak flow velocity during early diastole (E), peak flow velocity 
during atrial contraction (A) later in the disease. It also attenuated the loss in left ventricular 
fractional shortening.   
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A single intravenous injection of AAV2/9-CMV-Glo-I one week after the onset of DM also 
attenuated impairments in diastolic and systolic functions induced by diabetes.  However, 
compared to DM rats injected with AAV2/9-Endo-Glo-I, AAV2/9-CMV-Glo-I was less effective 
(p<0.05) in some cardiac parameters including E:A ratio, heart rate and left ventricular diameter 
in diastole (see Tables below Figures 3A and 3B).  As such, we focused on DM rats treated with 
AAV2/9-Endo-Glo-I for the rest of the study.  A single intravenous injection of the non-specific 
AAV2/9-Endo-eGFP one week after the onset of DM did not attenuate loss of diastolic and 
systolic dysfunctions later in the disease.   
 
Myocytes contractile kinetics 
Myocytes from DM rats were less tolerant to Ca2+reconstitution compared to myocytes from 
control animals and this resulted in about 20%-25% fewer viable ventricular myocytes compared 
to control.  However, the mean lengths of DM myocytes from Con and DM rats were similar.  
When stimulated at a frequency of 0.5 Hz, velocities of shortening and relengthening of DM 
myocytes were significantly slower (p < 0.05) than those of control myocytes (Figure 4A, 
representation traces above and mean data in table below).  Extent of shortening was also less in 
DM myocytes.  Injecting rats with AAV2/9-Endo-Glo-I one week after the onset of DM blunted 
the changes in velocities of shortening and relengthening, and extent of myocyte shortening.  
Injecting rats with AAV2/9-Endo-eGFP one week after the onset of DM did not attenuate the 
reduction in myocyte function loss.  Injecting control rats with AAV2/9-Endo-eGFP did not 
negatively impact myocyte contractile kinetics (Figure 4A, Table below). 
 
Evoked intracellular Ca2+ transients 
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Improvements in contractile kinetics of myocytes from DM rats treated with AAV2/9-Endo-Glo-I 
prompted us to assess whether evoked Ca2+ release from the sarcoplasmic reticulum (SR) was 
improved.  The efficiency of Ca2+ cycling out and into the SR is crucial for efficient and rhythmic 
contractions.  In Figure 4B, upper panels show representative evoked Ca2+ transients pictograms 
from ventricular myocytes isolated from Con, DM and AAV2/9-treated Con and DM animals.  
The mean rate of evoked Ca2+ release from DM myocytes was significantly slower than that in 
control myocytes.  In about 55% of DM myocytes assayed, evoked Ca2+ release was 
dyssynchronous (non-uniform) and spontaneous Ca2+ release occurred during diastole (Figure 4B 
pictograms, white arrows). Ca2+ transient decay time was also increased in DM myocytes (Figure 
4B, Table below).   Injecting rats with AAV2/9-Endo-Glo-I one week after the onset of DM 
blunted the reductions in evoked Ca2+ release from and reuptake into the SR seven weeks later.  It 
also blunted dyssynchronous/non-uniform Ca2+ release from the SR and spontaneous Ca2+ release 
occurred during diastole.  Injecting rats with AAV2/9-Endo-eGFP one week after the onset of 
DM did not blunt the reductions in evoked Ca2+ release from and reuptake into the SR.  Injecting 
control rats with AAV2/9-Endo-eGFP did not affect evoked Ca2+ release from and reuptake into 
the SR.  Summary data are shown in Table below Figure 4B.   
 
Microvessel perfusion and permeability  
In left ventricular tissues from control rats, the green fluorescence of injected BSA-FITC was 
visible throughout the entire microvascular networks (Figure 5A, upper panel), indicating that the 
tissues were efficiently being perfused with blood/nutrients.  The green fluorescence of BSA-
FITC was also confined to vascular networks.  The first noticeable difference in left ventricular 
tissues from DM rats was that the green fluorescence of BSA-FITC was diffusing out of the 
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microvessels, consistent with “leakage” or increased transcytosis (Figure 5A, middle panel).  The 
density of microvessels perfused with BSA-FITC (i.e., with green fluorescence) was also 
significantly reduced (p<0.05, Figure 5A middle panel and graphs), suggesting under 
perfusion/reduced perfusion of the ventricular microvasculature in DM rats.  Administration of a 
single intravenous injection of AAV2/9-Endo-Glo-I to rats one week after the onset of DM 
blunted loss of microvessel perfusion prevented the leakiness of the microvessels (Figure 5A 
lower panel, and graphs).  This increase in microvasculature perfusion was not seen in DM rats 
injected with AAV2/9-Endo-eGFP (Figure 5A).  Injecting control rats with AAV2/9-Endo-eGFP 
did not alter microvasculature perfusion or permeability.    
 
Expression/activities of VAP-1 and Glo-I  
In ventricular tissues from 8 week DM rats, Glo-I levels was reduced 3-fold and VAP-1 was 
increased 3.2-fold (Figure 5B).  Treating rats with AAV2/-Endo-Glo-I one week after the onset of 
DM, blunted VAP-1 upregulation and preserved Glo-I expression later in the disease.  Treating 
rats with AAV2/-Endo-eGFP one week after the onset of DM, did not prevent diabetes-induced 
alterations in VAP-1 and Glo-I expression (data not shown).   
Glo-I activity, determined by the formation of S-D-lactoylglutathione formation, was also ~50 % 
lower in ventricular tissues from DM rats (Table 2).  Injecting rats with AAV2/9-Endo-Glo-I one 
week after the onset of DM, minimally lowered serum MG.  However, it significantly reduced 
MG level in ventricular tissue (p<0.05, Table 2) to near that in control animals and the blunted 
loss of Glo-I activity.  Table 2, lower row also shows increased MG levels in hearts of DM rats 
that was blunted following a single injection with AAV2/-Endo-Glo-I one week after the onset of 
DM, prevented the increase in MG. 
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Expression and activities of SR Ca2+ cycling proteins 
Improvements in contractile kinetics and evoked Ca2+ transients following AAV2/9-Endo-Glo-I 
treatment also prompted us to measure the activities of the major SR Ca2+ release and uptake 
proteins, RyR2 and SERCA2a/PLN in myocytes. 
(a) SERCA2a: Steady state level of SERCA2a and its inhibitor protein phospholamban (PLN) in 
8 week DM rats were not significantly different from controls (Figure 5C).  There was also no 
significant change in the amount of phospho-PLN (Ser16, phospho-Ser 17, Figure 5C, 
autogradiograms).  However, the abilities of SERCA2a from DM rats to transport Ca2+ (E1→E2) 
and hydrolyze ATP were significantly lower than that of control animals (Figures 5C and 6A, 
p<0.05).  Administering a single intravenous dose of AAV2/9-Endo-Glo-I one week after the 
onset of DM also did not alter expression of SERCA2a, monomeric PLN, and pentameric PLN 
but it attenuated the loss in SERCA2a’s ability to transport Ca2+ (E1→E2) and hydrolyze ATP.  
Injecting rats with AAV2/9-Endo-eGFP one week after the onset of DM did not attenuate 
SERCA2a activity loss.  Injecting control rats with AAV2/9-Endo-eGFP did not impair the ability 
to transport Ca2+ and hydrolyze ATP (Figures 5C and 6A). 
(b) RyR2: After 8 weeks of DM, steady-state levels of RyR2 protein in DM hearts was not 
significantly different from control (Figure 6B).   However, the Ca2+-responsiveness (function) of 
RyR2 as assessed from its ability to bind the specific ligand [3H]ryanodine was altered (Figure 
6B).  At suboptimal Ca2+ (≤ 40 µM), RyR2 from DM animals bound more [3H]ryanodine after 2 
hrs, consistent with enhanced activity/opening at low [Ca2+].  Interestingly, at optimal Ca2+ (200-
300 µM), RyR2 from DM animals bound significantly less [3H]ryanodine than RyR2 from control 
animals, indicative of reducing activity/opening.  Injecting rats with AAV2/9-Endo-Glo-I one 
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week after the onset of DM restored Ca2+ activation of RyR2.  Injecting rats with AAV2/9-Endo-
eGFP one week after the onset of DM did not restore Ca2+ sensitivity.  Injecting control rats with 
AAV2/9-Endo-eGFP did not affect the Ca2+-sensitivity of RyR2 as measured using [3H]ryanodine 
binding assays, (Figure 6B).   
(c) MG adduct on RyR2 and SERCA2a: Previously we showed that impairments in activities of 
RyR2 and SERCA2a in hearts of chronic DM rats resulted in part from increased post-
translational modifications by MG (29, 39).  Since treatment of DM rats with AAV2/9-Endo-Glo-
I attenuated the increase in ventricular MG, we assessed formation of MG-adduct on RyR2 and 
SERCA2a were also attenuated.  Figures 6C and 6D show ~3-fold higher amounts of the 
argpyrimidine (an MG-derived adduct) on SERCA2a and RyR2 from DM animals compared with 
controls.  Injecting rats with AAV2/9-Endo-Glo-I one week after the onset of DM, attenuated 
formation of argpyrimidine adduct on SERCA2a and RyR2.  Injecting DM rats with AAV2/9-
Endo-eGFP did not attenuate the amount of argpyrimidine on SERCA2a and RyR2.  Injecting 
control rats with AAV2/9-Endo-eGFP one week after the onset of DM did not affect the 
formation of argpyrimidine adducts on SERCA2a and RyR2 (data not shown). 
 
Glutathione (GSH) and enzymes that regulate GSH level 
Since reduced glutathione (GSH) is a co-factor for Glo-I, GSH and GSSH levels, and the 
activities of the enzymes that regulate GSH levels were measured in heart tissues.   In this study, 
GSH:GSSG ratio was significantly lower (p<0.05) in ventricular tissues from DM rats compared 
with controls (1.55 ± 0.05, n = 5 hearts compared with 2.4 ± 0.2, n = 5 hearts). Injecting rats with 
AAV2/9-Endo-Glo-I one week after the onset of T1D, increased GSH/GSSG to near control 
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levels (2.3 ± 0.3, n = 6 hearts).  Administering AAV2/9-GFP to DM rats did not potentiate 
GSH/GSSG ratio (1.6 ± 0.3, n = 5 hearts).    
In hearts of DM rats (γ-glutamylcysteine ligase, the rate-limiting enzyme in the synthesis of 
GSH) and glutathione reductase (the enzyme that reduces oxidized glutathione) were decreased 
by 35% and 32%, respectively compared with  control (205.2 ± 1.2 mU/mg protein compared to 
470.5 ± 18.1 mU/mg protein and 32.5 ± 8 mU/mg protein compared to 48.1 ± 7.4 mU/mg 
protein).  Administering AAV2/9-Endo-Glo-I to DM rats restored the activities of γ-
glutamylcysteine ligase and glutathione reductase to near control levels (460 ± 20 mU/mg protein 
and 45.5 ± 10.1 mU/mg protein, respectively).  Administering AAV2/9-Endo-eGFP to DM rats 
did not significantly increase the activities of γ-glutamylcysteine ligase and glutathione reductase 
(210.5 ± 21.2 mU/mg protein and 30.5 ± 11.2 mU/mg).    
 
ROS and inflammation in ventricular tissues  
Earlier we showed that MG is a potent inducer of mitochondria ROS in cardiac myocytes (29).  
After 8 weeks of DM, basal mitochondria ROS was increased ∼3.5 fold in ventricular myocytes 
(Figure 7A).   Treating rats with AAV2/9-Endo-Glo-I one week after induction of DM, attenuated 
the increase in mitochondria ROS in ventricular myocytes.  Treating DM rats with AAV2/9-
Endo-Glo-I one week after induction of DM, In this study, mRNA level for the inflammatory 
marker TNF-α  was 3.2-fold higher in left ventricular tissues of DM rats compared to control 
(p<0.05, Figure 7B).  Figure 7C also shows a 3.8-fold increase in the amount of p-p65 of NF-κB 
in 8 week DM rats compared to control (p<0.05).  Injecting DM rats with AAV2/9-Endo-Glo-I 
significantly blunted the amount of TNF-α  mRNA and p65 phosphorylation.  Injecting DM rats 
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with AAV2/9-Endo-eGFP minimally attenuated the increase in p-p65 and TNF-α  mRNA (data 
not shown).  
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Gregg et al., (48) recently reported that although the incidence of micro- and macro-vascular 
diseases has declined in patients with DM over the past two decades, they are still 5-7 times 
higher than in non-DM individuals. These epidemiologic data suggest that additive therapies may 
be needed to complement glucose and lipid lowering agents if end-organ complications are to be 
reduced, especially in outpatient settings. One potential strategy could be to lower the supra-
physiological MG flux thought to be eliciting many of the pathobiologies seen in DC.   
Earlier, we showed that daily administration of scavengers of reactive carbonyl species 
(aminoguanidine and pyridoxamine) to DM rats attenuated DC development (29, 36).  Vulesevic 
et al., (49) also showed that increasing expression of the MG degrading enzyme Glo-I in bone 
marrow-derived macrophages and endothelial cells, protected against DC.  Very recently, Xue et 
al., (50) showed that administering a Glo-I inducer formulation (trans-resveratrol and hesperetin) 
to overweight and obese individuals for eight weeks attenuated fasting and post prandial glucose 
and inflammation, and improved arterial dilation.  Since low MG regulates a diverse array of 
cellular and physiologic processes, and since DM requires lifelong treatment, we extended the 
work to identify “the source” of heart failure-causing MG.  Glycolysis leak is unlikely since the 
primary source since the diabetic heart obtains 90-95% of the acetyl CoA needed for ATP 
production from β-oxidation of fatty acids (30). 
A key finding of the present study is that MG production/flux is increased in the heart during 
DM and this increase is arising from upregulation of VAP-1 in cSMCs (4-5 fold), and from 
reductions in Glo-I (3-4 fold) in SMCs and mycoytes.  These changes were seen in both Type 1 
and Type 2 DM, likely reflecting increases in oxidative stress and inflammation (46, 47).  They 
also complement data from other studies (35, 51, 52).  In this study we also showed that for the 
first time that preventing Glo-I downregulation in cSMCs and ventricular myocytes using a 
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custom-designed adeno-associated virus, attenuated DC development in a rat model of DM, 
establishing a direct relationship between increase in ventricular MG and heart failure.  
Attenuation in myocyte and cardiac function losses were also independent of blood glucose 
levels.   
In this study we found that preserving Glo-I levels it attenuated microvascular leakage, 
inflammation, loss of microvessel perfusion (hypoxia) in left ventricular tissues.  It also blunted 
impairments in blood flow velocity during early diastole (E) and blood flow velocity during atrial 
contraction. Dysregulation of endothelial cells (ECs) plays an important role in the pathogenesis 
of DC by altering vasodilator tone and permeability of microvessels (51).  When ECs lose their 
ability to vasodilate pressure builds up within the vasculature, increasing the likelihood of 
substances from the blood leaking into the surrounding tissues.  This was seen as green 
fluorescence (of BSA-FITC) emanating from small diameter arterioles (20 µm - 50 µm) and 
capillaries in left ventricular tissue of rats.  Why some but not all vessels become “leaky” is not 
well defined.  One explanation could be heterogeneity in VAP-1 expression and therefore the 
amount of MG produced by SMCs; MG impairs the function of ECs in a concentration-dependent 
manner (35).  Although capillaries do not contain SMCs, the function of their ECs could be 
negatively impacted by MG produced by cSMCs in upstream arterioles and met-arterioles.  In this 
study we also found a significant reduction in the density of microvessels perfused, suggesting 
impairment in nutrient supply to the myocytes.  This reduction in the density of microvessel 
perfusion could be the results of increased leakage of microvessels. 
Preventing Glo-I downregulation also preserved myocyte function. It blunted loss of 
ventricular contraction/relaxation, impairments in evoked contraction/relaxation kinetics, and 
dysregulation of Ca2+ cycling into and out of the SR by prevented dysregulation of RyR2 and 
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SERCA2 and reducing oxidative stress.  In this, MG production/flux in ventricular tissues from 
DM rats increased 8-fold (1585 nmol/200 mg tissue compared to 198 nmol/200 mg tissue for 
control).  At a first glace these results seems higher than the expected a 3-4 fold increase in MG  
based on the 3-4 fold increase in VAP-1 protein.  However, it should be pointed out that although 
VAP-1 and triose phosphate isomerase have similar affinities for their substrates (Km of 92 µM vs 
~120 µM), the Vmax for VAP-1 is >2-orders of magnitude faster than that of triose phosphate 
isomerase (54-55).  Also, since reduced glutathione levels in the extracellular environment are 
low, significantly more of the MG produced by VAP-1 in the extracellular will be in the unbound 
state compared to MG inside cells (56).  Earlier we showed that exposing rat ventricular 
myocytes to 20-25 µM MG perturb SR Ca2+ and increase mitochondria ROS production (29).  
To date, the specific mechanisms by which increasing Glo-I in cSMCs of DM rats down-
regulated VAP-1 expression remains undefined.  What we know is that the VAP-1 gene (AOC3) 
is transcriptionally regulated by NF-κB (57) and that MG activates NF-κB (58).  Reducing MG in 
cSMCs by increasing Glo-I prevents NF-κB activation (p-P65) which in turn blunts VAP-1 
upregulation.  Preventing Glo-I downregulation also blunted TNF-α (inflammation) increase in 
hearts of DM rats. Although we did not specifically assess macrophage and neutrophil infiltration 
the primary sources of TNF-α production, we did assess “leakiness/permeability” of microvessels, 
which promotes macrophage and neutrophil infiltration in DM rats (35, 49, 59).   
AAV serotypes exhibit selective tropism for certain cell types.  In the heart, AAV2/9 shows 
preferential tropism for SMCs and myocytes (35, 60).  Endothelin-1 is also synthesized by 
macrophages. By cloning the endothelin-1 promoter in front of Glo-I cDNA, we were able to 
selectively target expression of Glo-I protein in SMCs and myocytes in the heart.  Using this 
custom-designed virus, we found that preventing Glo-loss in ventricular tissues (SMCs and 
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myocytes) of DM rats was sufficient to blunt DC development.  What if any would be the 
consequences of increasing Glo-I in SMCs and myocytes of DM to levels significantly greater 
than that in non-diabetics remain to be determined.  In the vasculature, endothelin-1 is 
synthesized by smooth muscle cells and endothelial cells (61).  By cloning the endothelin-1 
promoter in front of Glo-I cDNA, we were able to preferentially target expression of Glo-I protein 
in the heart to SMCs and myocytes.  Our custom-designed virus restored Glo-I protein in 
ventricular tissues of Type 1 DM rats to levels similar to that in Con rats.  What if any would be 
the functional consequences of increasing Glo-I in hearts of DM to levels significantly greater 
than that in non-diabetics remains to be determined.  Also, it is not clear whether increasing Glo-I 
in cSMCs only would be sufficient to attenuate heart failure. 
In the present study we also found that single injection of AAV2/9-Endo-Glo-I one week after 
the onset DM significantly reduced polydipsia and overnight polyuria seven weeks later.  It also 
prevented impairment in nest construction, which requires the complex interplay of attention, 
decision-making, motor function, and orofacial and forelimb movements. Although the 
mechanism(s) responsible for these effects are not clear, we expect systemic injection of AAV2/9-
Endo-Glo-I will infect SMCs (and possible other cells) throughout the vasculature. These are 
exciting observations that could have implications in the management of other end-organ deficits 
in DM. 
In summary, the present study shows that MG production/flux is increased in the heart during 
DM, and this increase arises from upregulation of VAP-1 in cSMCs (4-5 fold), and from 
reductions in Glo-I (3-4 fold) in SMCs and mycoytes.  This increase in MG production/flux leads 
to increased vascular permeability, a reduction in density of micro-vessels perfused, 
inflammation, and oxidative stress.  It also results in post-translational modification and 
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dysregulation of RyR2 and SERCA2 (and possibly other proteins), perturbation in myocyte 
intracellular Ca2+ cycling and impairment in myocyte contraction/relaxation (Figure 7D).   
Preserving Glo-I protein in cSMCs and myocytes blunted DC development.   
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FIGURE LEGENDS 
Table1:  Overview of patient samples used in the study.  Values shown are mean ± S.E.M. for 
n = 15-19 samples where indicated. * denotes significant difference from non-diabetic (p<0.05). 
 
 
 
 
Table 2: General characteristics of animals used for the study. Values shown are mean ± S.E.M. 
for n = ≥14 animals per group. * denotes significant difference from Con (p<0.05), # denotes 
significant difference from DM (p<0.05).    
 
 
 
Figure 1: Steady-state levels of VAP-1, Glo-I, and argpyrimidine (MG adduct formed on 
arginine residues or proteins) in coronary microvessels from left ventricular tissues from 
non-diabetic and diabetic patients.  Panel A shows representative immuno-histochemical 
staining for alpha smooth muscle actin (SM22-α, red) and VAP-1 (green) in smooth muscle cells 
from autopsied left ventricular tissues from two non-diabetic (upper two), two Type 1 DM 
(middle two) and two Type 2 DM (lower two) patients.  Graph on right shows mean ± S.E.M. for 
n ≥50 vessels obtained from N≥3 patients per group.  Panel B shows representative immuno-
histochemical staining for alpha smooth muscle actin (SM22-α, red) and Glo-I (green) in smooth 
muscle cells from autopsied left ventricular tissues from two non-diabetic (upper two), two Type 
1 DM (middle two) and two Type 2 DM (lower two) patients.  Graph on right show mean ± 
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S.E.M. for n ≥50 vessels obtained from N≥3 patients per group.  Panel C shows representative 
immuno-histochemical staining for alpha smooth muscle actin (SM22-α, green) and 
argpyrimidine (red) in smooth muscle cells and myocytes from autopsied left ventricular tissues 
from two non-diabetic (upper two), two Type 1 DM (middle two) and two Type 2 DM (lower 
two) patients.  Graph on right shows mean ± S.E.M. for n ≥50 vessels obtained from N≥3 patients 
per group. White bar at bottom of images = 50 µm. White arrows are included to emphasize the 
presence/lack of over overlapping staining. * denotes significant difference from Con (p<0.05). 
 
 
Figure 2: Steady-state levels of VAP-1, Glo-I, and argpyrimidine (MG surrogate) in 
coronary microvessels from left ventricular tissues from non-diabetic and diabetic rats. 
Panel A shows representative immuno-histochemical staining for alpha smooth muscle actin 
(SM22-α, red) and VAP-1 (green) in smooth muscle cells from left ventricular tissues from two 
non-diabetic (upper two) and two STZ-Type 1 DM rats.  Graph on right show mean ± S.E.M. for 
n ≥40 vessels obtained from N≥5 animals per group.   Panel B shows representative immuno-
histochemical staining for alpha smooth muscle actin (SM22-α, red) and Glo-I (green) in smooth 
muscle cells from left ventricular tissues from two non-diabetic (upper two) and two STZ-Type 1 
DM rats.  Graph on right show mean ± S.E.M. for n ≥40 vessels obtained from N≥5 animals per 
group. Panel C shows representative immuno-histochemical staining for alpha smooth muscle 
actin (SM22-α, green) and argpyrimidine (red) in left ventricular smooth muscle cells and 
myocytes from tissues from two non-diabetic (upper two) and two STZ-Type 1 DM rats.  Graph 
on right show mean ± S.E.M. for n ≥40 vessels obtained from N≥5 animals per group. White bar 
at bottom of images = 50 µm. White arrows are included to emphasize the presence/lack of over 
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overlapping staining.  Panels D shows overnight nest construction of animals used in the study.  
Graph below shows mean ± S.E.M. for n = 5-6 animals per group. For all panels, * denotes 
significant difference from Con (p<0.05), and # denotes significant difference from DM (p<0.05). 
 
  
 
Figure 3: In vivo cardiac function of hearts from control, DM and DM-treated rats.  Panel A 
upper shows representative pulse-wave echocardiograms of hearts from control, DM, AAV2/9-
Endo-Glo-I-treated DM and AAV2/9-CMV-Glo-I-treated DM rats.  For this, rats were 
anesthetized with 3% isoflurane and after securing the rats with tape in the supine position on a 
heated (37°C) pad, maximal early (E) and late (A)  diastolic transmitral flow velocities were 
measured in the short axis orientation using a color flow–guided, pulsed-wave Doppler probe 
(716, 17.6 MHz).  Mean ± S.E.M data for peak flow velocity during early diastole (E), peak flow 
velocity during atrial contraction (A) and E: A ratios for n = 18-20 animals are listed in the table 
below. Panel B upper shows representative M-mode echocardiograms from control, DM, 
AAV2/9-Endo-Glo-I-treated DM and AAV2/9-CMV-Glo-I-treated DM rats.  For this, rats were 
anesthetized with 3% isoflurane and a 4MHz linear array pediatric probe was then placed in the 
parasternal, short axis orientation while maintaining normothermia with a heating pad. Three 
loops of M-mode data were captured for each animal, and the data was averaged from at least 5 
beat cycles/loop. Mean ± S.E.M hemodynamic data for n = 18-20 animals are listed in the table 
below.  
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Figure 4: Function of left ventricular myocytes from control, DM and DM-treated rats.  
Panel A shows representative contractile profile of ventricular myocyte isolated from control, 
AAV2/9-Endo-eGFP-treated Con, DM, AAV2/9-Endo-eGFP-treated DM and AAV2/9-Endo-
Glo-I-treated DM rats. For this, myocytes in DMEM medium were placed in a Warner chamber 
mounted on the stage of an inverted microscope (Zeiss, X-40) at room temperature (22°C–24°C). 
Cells were then field stimulated (10 V) for 10 ms at 0.5 Hz, using a pair of platinum wires placed 
on opposite sides of the chamber. Extent of myocyte shortening and rates of shortening and 
relengthening were determined using IonWizard Version 5.0. Mean ± S.E.M for n >120 cells 
from N= 5 animals are listed in the table below. Panel B shows representative line scan images of 
Ca2+ transients from control, AAV2/9-Endo-eGFP-treated Con, DM, AAV2/9-Endo-eGFP-treated 
DM and AAV2/9-Endo-Glo-I-treated DM rats preloaded with Fluo-3AM and field stimulated at 
0.5 Hz. White arrows in indicate regions of dyssynchronous (non-uniform) Ca2+ from the SR and 
diastolic Ca2+ release.  Mean ± S.E.M for n >80 cells from N= 5 animals are listed in the table 
below. For all panels, * denotes significant difference from Con (p<0.05), and # denotes 
significant difference from DM (p<0.05). 
 
Figure 5: Panel A left shows representative images of BSA-FITC in left ventricular tissues from 
Con, DM, and AAV2/9-Endo-Glo-I-treated DM rats. For this, rats were injected with BSA-FITC 
(40 mg/kg) 10 min prior to sacrifice.  After this, animals were sacrificed, and hearts were 
removed and immersed in 4% paraformaldehyde for 24 hrs followed by 30% sucrose. Twenty 
micrometer longitudinal sections, were then placed on pre-cleaned glass slides, mounting medium 
containing DAPI was added and images were then taken at 100X.   Graphs on right side show 
relative density of microvessel (>20 µm) perfused with BSA-FITC per 100X frame and the 
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number of microvessels from which BSA-FITC was seen emanating.  Values are mean ± S.E.M 
from n >20 sections from N= 5 rats. White bar at bottom of each image = 50 µm. Panel B shows 
representative autoradiograms for VAP-1 and Glo-I in hearts from Con, DM, and AAV2/9-Endo-
Glo-I-treated DM rats, normalized to β-actin.   Data shown in graph below are mean ± S.E.M 
from N= 5 rats done in duplicate. Panel C upper shows representative autoradiograms for 
SERCA2a, monomeric and pentameric PLN and β-actin in hearts from control, AAV2/9-Endo-
eGFP-treated Con, DM, AAV2/9-Endo-eGFP-treated DM and AAV2/9-Endo-Glo-I-treated DM 
rats.   Data shown in graph below are mean ± S.E.M (N= 5 rats done in triplicate) for ATP-
stimulated Ca2+ uptake (SERCA2a function) in vesicular preparations from control, AAV2/9-
Endo-eGFP-treated Con, DM, AAV2/9-Endo-eGFP-treated DM and AAV2/9-Endo-Glo-I-treated 
DM rats.  
   
Figure 6: Panel A shows mean ± S.E.M (N= 5 rats done in triplicate) for ATP hydrolysis 
(SERCA2a function) in vesicular preparations from control, AAV2/9-Endo-eGFP-treated Con, 
DM, AAV2/9-Endo-eGFP-treated DM and AAV2/9-Endo-Glo-I-treated DM rats. Data shown in 
graph below are mean ± S.E.M from N= 5 rats done in duplicate. Panel B shows Ca2+-dependent 
binding [3H]ryanodine to RyR2 from control, AAV2/9-Endo-eGFP-treated Con, DM, AAV2/9-
Endo-eGFP-treated DM and AAV2/9-Endo-Glo-I-treated DM rat hearts.  Significance notations 
were left out to aid in data clarity. For all panels, * denotes significant difference from Con 
(p<0.05), and # denotes significant difference from DM (p<0.05).  Panel C upper shows 
representative autoradiograms for argpyrimidine on SERCA2 from in SR membrane preparations 
from control, DM, and AAV2/9-Endo-Glo-I-treated DM rat hearts.   Data shown in graph below 
are mean ± S.E.M for N= 5 separate preparations assayed in duplicate. Panel D upper shows 
52 
 
representative autoradiograms for argpyrimidine on RyR2 from in SR membrane preparations 
from control, DM, and AAV2/9-Endo-Glo-I-treated DM rat hearts.   Data shown in graph below 
are mean ± S.E.M for N= 5 separate preparations assayed in duplicate.  
 
  
Figure 7: Panel A left shows representative Mitotracker Green (mitochondria) and MitoSox red 
(ROS) staining in left ventricular myocytes isolated from control, DM, and AAV2/9-Endo-Glo-I-
treated DM rat hearts.  Data in graph on right are mean ± S.E.M for MitoSox staining obtained 
from >40 myocytes obtained N= 5 animals.  Panel B shows relative amounts of TNF-α mRNA in 
left ventricular tissues from control, DM, and AAV2/9-Endo-Glo-I-treated DM rat hearts.  Values 
shown in graph are mean ± S.E.M from N = 5-6 rats per group, normalized to actin.   Panel C 
shows representative autoradiograms for phosphorylated NF-κB (p65) in left ventricular lysates 
from control, DM, and AAV2/9-Endo-Glo-I-treated DM rat hearts.   Values shown in graph 
below are mean ± S.E.M from N = 5-6 rats per group.   Panel D shows a schematic model 
summarizing data obtained from this study and a proposed mechanism by which increased 
production of MG by SMCs lead to the development of DC.   
 
 
 
 
  
53 
 
Table 1: Overview of patient samples used in the study 
 
Non-
DIABETIC 
      
Number of 
samples 
Mean age 
(yrs) 
Males Female Duration 
of DM 
HbA1c (%) Time to 
tissue 
collection 
(hr) 
15 63.3 ± 3.9 10 5  4.5 ± 1.4 10.9 ± 2.4 
       
DIABETIC       
Number of 
samples 
Mean age 
(yrs) 
Males Female Duration 
of DM 
HbA1c (%) Time to post 
mortem (hr) 
19 68.8 ± 2.1 11 
(three Type 1  
and eight Type 2) 
8 
(one Type 1,  
seven Type 2) 
26.5 ± 5.9 7.25 ± 0.5 9.9 ± 2.9 
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Table 2: General characteristics of animals used in the study 
 
PARAMETER    Control  
 
 
 
n = 14 
Control 
treated 
withAAV2/9- 
Endo-eGFP 
n = 14 
Diabetic 
 
 
 
n = 20 
Diabetic 
treated with 
AAV2/9-
Endo-Glo-I 
n = 20 
Diabetic 
treated with 
AAV2/9-
Endo-Glo-I 
n = 20 
Diabetic 
treated with 
AAV2/9-
CMV-Glo-I 
n = 18 
 
Body mass (g) 
 
415.2 ± 10.2 
 
401.3 ± 11.4 
 
275.4 ± 15.2* 
 
290.4 ± 12.3* 
 
320.3 ± 10.3# 
 
315.2 ± 15.2# 
Heart weight 1.2  ± 0.2 1.2 ± 0.2 1.0 ± 0.3 1.0 ± 0.3 1.1 ± 0.2 1.1 ± 0.2 
Heart to body 
weight ratio (mg/g) 3.0 ± 0.2 3.0 ± 0.2 3.6 ± 0.3 3.5 ± 0.3 3.4 ± 0.3 3.4 ± 0.3 
Blood glucose 
(mmol) 5.5 ± 1.6 6.3 ± 1.7 25.6 ± 4.5* 24.1 ± 3.5 22.9 ± 3.2 22.1 ± 4.2 
% Glycated 
hemoglobin 4.2 ± 0.3 4.3  ± 0.4 7.6 ± 0.2* 7.5 ± 0.3* 7.2 ± 0.5 7.3 ± 0.6
# 
Serum insulin  
(ng/mL) 0.9 ± 0.2 1.0 ± 0.1 0.3 ± 0.1* 0.3 ± 0.1* 0.6 ± 0.1
# 0.4 ± 0.2 
Serum TBARS1 
(nmol/mL) 2.4 ± 0.3 2.5 ± 0.6 12.0 ± 2.1* 11.5 ± 1.9* 7.5 ± 1.0
# 9.8 ± 1.2 
SSAO activity2 
(units/mL/min) 0.3 ± 0.02 0.3 ± 0.03 0.7 ± 0.1* 0.7 ± 0.1* 0.6 ± 0.0
# 0.6 ± 0.0# 
Serum MG (µM) 0.3 ± 0.1 0.3 ± 0.1 1.2 ± 0.2* 1.4 ± 0.2* 1.2 ± 0.3 1.4 ± 0.2# 
Ventricular MG 
(nmol/200 mg) 
197.8 ± 
34.2 
203.7 ± 
46.5 
1588.5 ± 
174.7* 
1790.7 ± 
205.8* 
184.4 ± 
30.2# 
475.5 ± 
110.7# 
Ventricular 
Glyoxal (nmol/200 
mg) 
252.8 ± 
32.2 
330.6 ± 
90.5 
3110.5 ± 
184.7* 
3326 5 ± 
205.8* 
356.4 ± 
30.2# 
654.5 ± 
95.7# 
Glo-I activity 
(µmol/min/100 mg 
ventricular tissue) 
10.2 ± 1.0 
 
11.4 ± 1.0 5.1 ± 0.8* 6.3 ± 0.6* 13.2 ± 1.2# 12.1 ± 1.6# 
VAP-1 activity 
(units/min/100 mg 
ventricular tissue)  
0.2 ± 0.0 
 
0.2 ± 0.0 1.4 ± 0.1* 1.4 ± 0.1* 0.4 ± 0.0# 0.5 ± 0.1# 
 
* = significantly different from control (p<0.05), # = significantly different from diabetic 
       (p<0.05) 
  
1 - TBARS, Thiobarbituric acids reactive substances; 2 - SSAO, semicarbazide-sensitive  
      amine oxidase 
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